Palbocent (Palbociclib) 125 MG – 21 Capsules

Description

Summary:

Looking to buy Palbocent online at an affordable cost? Palbocent 125 mg is a prescription targeted therapy containing Palbociclib 125 mg, a selective CDK4/6 inhibitor used to treat hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer. Manufactured by Incepta Pharmaceuticals Ltd., this medicine is commonly prescribed in combination with an aromatase inhibitor or fulvestrant to help slow cancer cell growth and improve treatment outcomes.

If you’re comparing the Palbocent 125 mg price or searching for the current Palbociclib 125 mg price, our international pharmacy offers genuine export-quality medication at competitive rates. The current Palbocent 125 mg price starts from $80.00 per pack of 21 capsules, making it a cost-effective alternative for eligible patients worldwide. Whether you want to buy Palbocent online for ongoing treatment with secure international shipping, we provide reliable service to patients across the USA, UK, Australia, Canada, Europe, the Middle East, and many other countries.

Product Overview

Palbocent 125 mg contains Palbociclib INN 125 mg in each capsule. Palbociclib belongs to a class of medicines known as cyclin-dependent kinase (CDK) 4/6 inhibitors. It works by blocking CDK4 and CDK6 enzymes that drive cancer cell division, preventing tumor cells from progressing from the G1 phase to the S phase of the cell cycle. This targeted mechanism helps reduce the growth and spread of hormone receptor-positive breast cancer cells.

Clinical studies have shown that combining Palbocent 125 mg with endocrine therapies such as letrozole or fulvestrant significantly improves treatment effectiveness compared with endocrine therapy alone. The combination reduces retinoblastoma (Rb) protein phosphorylation, suppresses E2F signaling, increases cancer cell senescence, and inhibits tumor growth more effectively. If you are researching the Palbociclib 125 mg price or planning to buy Palbocent as part of your prescribed treatment plan, consult your oncologist to determine whether this targeted therapy is appropriate for your condition.

Palbocent 125: Each capsule contains Palbociclib INN 125 mg.

Product Features of  Palbocent 125 mg:

Palbocent 125mg Price: $80.00

Palbocent (Palbociclib)  is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Cyclin D1 and CDK4/6 are downstream of signaling pathways which lead to cellular proliferation. It reduced cellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progression of the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with the combination of Palbociclib and antiestrogens leads to decreased retinoblastoma (Rb) protein phosphorylation resulting in reduced E2F expression and signaling, and increased growth arrest compared to treatment with each drug alone.

In vitro, treatment of ER-positive breast cancer cell lines with the combination of palbociclib and antiestrogens resulted in a significant increase in cell senescence. This effect was more pronounced than using the drug alone. Extended senescence persisted for up to 6 days after removal of Palbocent. The effect was further amplified when antiestrogen therapy was continued. In vivo studies using patient-derived ER-positive breast cancer xenograft models have shown significant results. The combination of Palbocent and letrozole leads to an increased inhibition of Rb phosphorylation. It also enhanced the suppression of downstream signaling. This combination therapy was more effective in inhibiting tumor growth than each drug used alone.

In a separate in vitro study, human bone marrow mononuclear cells were treated with palbociclib. Whether treated with or without anti-estrogens, these cells did not become senescent. In addition, they recurred after the withdrawal of palbociclib.

Palbociclib uses in specific population

Pregnancy

Based on findings from animal studies and its mechanism of action. Palbocent 125 can cause fetal harm when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. In animal reproduction studies, the administration of Palbocent to pregnant rats and rabbits during organogenesis resulted in embryo-fetal toxicity at maternal exposures that were ≥4 times the human clinical exposure based on AUC.

Pregnant women should be advised about the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.

Lactation

There is no information regarding the presence in human milk, its effects on milk production, or the breastfed infant. Because of the potential for serious adverse reactions in breastfed infants from Palbociclib, advise a lactating woman not to breastfeed during treatment with Palbociclib and for 3 weeks after the last dose.

Pediatric Use: The safety and effectiveness in pediatric patients have not been established.

Geriatric Use: No overall differences in safety or effectiveness were observed between these patients and younger patients.

Hepatic Impairment: Mild hepatic impairment had no effect on the exposure of Palbociclib. The pharmacokinetics of Palbociclib has not been studied in patients with moderate or severe hepatic impairment.

Renal Impairment: 

For more Oncology medicine, visit our SHOP